The atlas / four different kinds of finding
Four entries do not make a league table
Immune regulation, mouse performance, experimental repair and human weight change occupy different places. No trial here put all four compounds in competition.
Same shelf, different questions
A paper about immune regulation, a mouse on a treadmill, a vessel-growth experiment and a weight trial can all end up under “peptides.” That shelf label is useful for finding them. It is poor evidence that they answer the same question.
An atlas can hold all four without pretending they occupy the same territory. The useful comparison is between the question asked, the subjects studied and the outcome measured.
The result changes when the question changes
| Entry | Finding | Where it stops |
|---|---|---|
| Thymosin alpha-1 | TESTS did not establish better sepsis survival | This result addresses sepsis survival; other immune settings require their own evidence. |
| MOTS-c | Treated mice performed better in physical tests | The dialysis cohort measured a human marker; it did not test treatment. |
| BPC-157 | Vessel growth increased in experimental models | The human safety pilot had two adults and did not measure injury repair. |
| Tirzepatide | Human trials measured weight and glucose reductions | Group benefits coexist with gastrointestinal effects and a biliary safety signal. |
The gap between an attractive explanation and a measured outcome is the revealing comparison for me. Thymosin alpha-1 has a substantial human research history, yet its strongest sepsis trial was disappointing. MOTS-c has an unusually interesting cellular origin without a proven human treatment benefit. Those are different situations, not interchangeable forms of “promising.”
Curiosity does not need a winner
MOTS-c’s journey to the nucleus earns my vote for the strangest piece of biology in this set. A cellular journey, however, cannot compete with a treatment result. Tirzepatide has the clearest large human comparisons for the metabolic outcomes discussed here, while the BPC-157 review makes plain how small its human evidence remains.
I see no useful winner for the whole shelf. Those stopping points matter more than a verdict on “peptides” as a class. The reading list is the place to take any of these arguments back to the papers.